Australasian
Cytometry
Society

ACS GUIDELINE FOR FLOW CYTOMETRIC ASSESSMENT OF HLA ALLOANTIBODIES

Second Edition 2020

Australasian Cytometry Society Guideline Document

Paper-based publications

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to via e-mail to:
clinicalguidelines@cytometry.org.au

Internet sites
This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the ACS.
Requests and inquiries concerning reproduction and rights are to be sent via email to:
clinicalguidelines@cytometry.org.au

First published 2017

Second edition 2020

CONTENTS

SCOPE v

ABBREVIATIONS vi

DEFINITIONS vi

INTRODUCTION 1

BACKGROUND 2

1. PRE ANALYTICAL PHASE 3

G1.1 Specimen Collection 3

G1.2 Specimen Transport 5

G1.3 Reagents 5

G1.4 Fluorochrome Labelled Antibodies 6

G1.5 Computer Software 7

2. ANALYTICAL PHASE 7

G2.1 Negative Control 7

G2.2 Positive Control 8

G2.3 PBMC Isolation 8

G2.4 Pronase Treatment 9

G2.5 Serum Samples 10

G 2.6 Flow Cytometric Cross Match Assay 11

G 2.7 Instrument Setup and Calibration 11

G 2.8 Sample Acquisition 12

G2.9 Performance Measures 13

3. POST ANALYTICAL PHASE 14

3.1 Results 14

3.2 Reports 14

REFERENCES CITED 15

PROCEDURAL REFERENCES 16

The Australasian Cytometry Society (ACS) was established in 1979 and incorporated in 1992 with the aim of promoting research, development and applications in, and to disseminate knowledge of flow cytometry.
A function of the ACS is to assist with development and application of clinical flow cytometry applications for hospitals and laboratories in the diagnosis and treatment of disease. This includes the preparation of guidelines and education programs.
Guidelines produced by the ACS are issued as reference material to provide laboratories and accrediting agencies with minimum requirements for testing considered acceptable for good laboratory practice.
Failure to follow these guidelines may pose a risk to public health and patient safety.

SCOPE

The '*Guidelines for Clinical Flow Cytometry Laboratory Practice'* is an ACS document to be read in conjunction with the NPAAC Standards document *'Requirements for Medical Pathology Services*' or IANZ equivalent. The latter is the overarching document broadly outlining Standards for good medical pathology practice where the primary consideration is patient welfare, and where the needs and expectations of patients, Laboratory staff and referrers (both for pathology requests and inter-Laboratory referrals) are safely and satisfactorily met in a timely manner.

Whilst there must be adherence to all the Requirements in the NPAAC Standards document, reference to specific Standards in that document are provided for assistance under the headings in this document.

The NPPAC Requirements encompass:

- documentation and accurate patient identification systems to minimise clerical errors and misidentification
- retention of records, data and documentation
- requirements necessary for the use of computers and computer software in clinical flow cytometry Laboratory practice
- quality assurance and quality control programmes for reagents, techniques and personnel

The '*Guidelines for Clinical Flow Cytometry Laboratory Practice*' document is a consensus recommendation by ACS members and associates for best medical laboratory practice for a procedure, method, staffing resource or facility. It encompasses any measures, procedures or considerations unique to operation of a clinical flow cytometry laboratory where they differ from a routine clinical pathology laboratory. It is a guideline not a standard.

The '*Guidelines for Clinical Flow Cytometry Laboratory Practice'* document is for use by clinical flow cytometry Laboratory personnel for the purpose of clinical flow cytometry testing and safe laboratory practice. In house departmental laboratory procedural and quality control documentation eg Haematology or Immunology Departments should be read in conjunction with this ACS document.

For details on procedural matters and methodologies readers are directed to the Reference List at the end of this document for ACS recommended published peer reviewed texts, articles and guidelines. Definitions given above are sourced from NPAAC.

.

ABBREVIATIONS

ºC	degrees Celsius
ACD	acid citrate dextrose, an anticoagulant
APHIA	Asia-Pacific Histocompatibility and Immunogenetics Association
ASHI	American Society for Histocompatibility and Immunogenetics
CD	Cluster of Differentiation
CDC	Complement Dependent Cytotoxicity
CO_2	Carbon Dioxide
DSA	Donor specific antibodies
FLXM	Flow Cytometric Lymphocyte Crossmatch
g	Relative centrifugal force (RCF)
HLA	Human Leucocyte Antigen
IgG	Immunoglobulin G
IVD	in-vitro diagnostic
MCS	Mean Channel Shift
µL	microlitre
PBMC	Peripheral Blood Mononuclear Cells
PBS	Phosphate Buffered Saline
RBC	Red Blood Cell
XM	Crossmatch

DEFINITIONS

Term	Definition
Acceptable mismatch	A non-self HLA antigen to which a recipient has no antibody reactivity, prior to transplantation.
Antibody cocktail	A mixture of more than one antibody.
B-cells	Bone marrow matured lymphocytes that express membrane bound immunoglobulin. In response to antigen contact these differentiate into antibody secreting plasma cells or memory B cells.
Bw4, Bw6	Public serologically detectable antigenic determinants that co-migrate with HLA-B antigens (and some HLA-A).
Complement dependent cytotoxicity (CDC)	A laboratory test to identify presence of antibodies in a serum sample using lymphocytes as targets and cell viability as the read-out.
CD	Cluster definition number used to identify individual cell markers e.g. CD3 for the pan T cell antigen
Crossmatch test (XM)	A test to identify antibody mediated reactivity to target antigens in a potential organ donor. The test report must be either positive or negative.
DR51, DR52, DR53	Serologically defined class II surface specificities encoded by DRB5*, DRB3* and DRB4* genes respectively
Competent clinical flow cytometrist	means a person who has a minimum of two years clinical flow cytometry experience, and who has been documented to be competent in clinical flow cytometry according to the Laboratory's Quality System
$F(ab')_2$	Divalent fragment of IgG generated following pepsin digestion of whole IgG
Fc receptor	A cell surface molecule specific for the heavy chain of certain immunoglobulin classes. Various forms found on lymphocytes, macrophages, natural killer cells and mast cells.
Guideline	means a consensus recommendation for best medical laboratory practice for a procedure, method, staffing resource or facility
Guidelines for Clinical Flow Cytometry Laboratory Practice	means the overarching document broadly outlining standards for good clinical flow cytometry laboratory practice where the primary consideration is patient welfare, and where the needs and expectations of patients, Laboratory staff and referrers (both for pathology requests and inter-Laboratory referrals) are safely and satisfactorily met in a timely manner.

Human Leucocyte Antigens (HLA)	Cell surface molecules determined by highly polymorphic linked genes on chromosome 6 (HLA-A, -B, -Cw, -DR, -DQ, -DP: the major histocompatibility complex or MHC).
HLA class I molecules	HLA-A, -B and –Cw molecules with structural and functional similarity. Expressed by almost all nucleated cells and platelets.
HLA class II molecules	HLA-DR, -DQ and –DP molecules with structural and functional similarity. Constitutively expressed only on specialised antigen presenting cells but may be inducible.
In-house IVD	means an IVD that is developed de novo, or developed or modified from a published source, or developed or modified from any other source, or its intended purpose, within the confines or scope of a Laboratory or Laboratory network, and is not supplied for use outside the Laboratory or Laboratory network. Commercial IVDs being used clinically for a purpose other than that originally intended by the manufacturer are also classed as in-house IVDs and are subject to the requirements of this standard.
In vitro diagnostic medical device (IVD)	means a medical device test if it is a reagent, calibrator, control material, kit, Specimen receptacle, software, instrument, apparatus, equipment or system, whether used alone or in combination with other diagnostic goods for in vitro use. It must be intended by the manufacturer to be used in vitro for the examination of Specimens derived from the human body, solely or principally for the purpose of giving information about a physiological or pathological state, a congenital abnormality or to determine safety and compatibility with a potential recipient, or to monitor therapeutic measures. The definition of an IVD does not encompass products that are intended for general Laboratory use that are not manufactured, sold or presented for use specifically as an IVD.
Lymphocyte	Mononuclear leukocytes of various lineages (B cell, T cell, NK cell).
Median Fluorescent Intensity (MFI)	A semi-quantitative readout of the degree of antibody binding, indirectly measured by a fluorescent label.
Platelets	Small, irregular blood borne anucleate cells which are an important component of a thrombus (clot).
Quality Assessment	means a measurement and monitoring function of quality assurance for determining how well health care is delivered in comparison with applicable standards or acceptable bounds of care.

Quality Assurance	means part of quality management focused on providing confidence that quality requirements will be fulfilled.
Quality control	means the study of those errors that are the responsibility of the Laboratory, and the procedures used to recognise and minimise them. This study includes all errors arising within the Laboratory between the receipt of the Specimen and the dispatch of the report. On some occasions, the responsibility of the Laboratory may extend from the collection of the Specimen from the patient and the provision of a suitable container, to the dispatch and delivery of the report. Internal quality control: means processes and activities that are used within the Laboratory to monitor the day-to-day operational and analytical performance of test procedures. These activities may include on-going instrument standardisation checks, instrument maintenance, analysis of control material, statistical or graphical assessment of results from control material.
Rituximab	Brand of therapeutic chimeric CD20-specific monoclonal antibody.
Sensitisation	An immune response to an antigen resulting in T and/or B cell memory.
Stain	means bind monoclonal antibodies to markers on cells of interest to
Standard	Means a minimum requirement for a procedure, method, staffing resource or laboratory facility that is required before a laboratory can attain accreditation
T cell	Mononuclear leukocyte having developed in the thymus.

INTRODUCTION

This ACS document is intended to be used in clinical flow cytometry Laboratories to provide guidance on good practice in relation to flow cytometry and to assist assessors carrying out Laboratory accreditation assessments.

These Guidelines are intended to serve as consensus recommendations for best medical laboratory practice, have been developed by ACS members and associates with reference to other guidelines as published in peer reviewed journals. The ACS is the pre-eminent specialist society in clinical flow cytometry Laboratory practice in Australasia and New Zealand and has developed a number of guidelines relevant to this document.

These are Guidelines and not Standards. These Guidelines should be read in conjunction with the current version of the NPAAC Standards Tier 2 document *'Requirements for Medical Pathology Services'* or IANZ equivalent.

For clarification Standards are described:

• A Standard is the minimum requirement for a procedure, method, staffing resource or laboratory facility that is required before a laboratory can attain accreditation. The use of the verb 'must' in standards indicates mandatory requirements for pathology practice.

In each section of this document, points deemed important for practice are identified as either 'Guidelines' or 'Commentaries', as follows:

• A Guideline is a consensus recommendation for best medical laboratory practice for a procedure, method, staffing resource or facility. Guidelines are prefaced with a 'G' (e.g. G2.2). The use of the word 'should' in each Guideline within this document indicates a recommendation for good pathology practice.

• A Commentary may be provided to give clarification to the Guidelines as well as to provide examples and guidance on interpretation. Commentaries are prefaced with a 'C' (e.g. C1.2) and are placed where they add the most value.

Appendices if attached to this document are informative**,** that is explanatory in nature and may provide examples or information of a clinical nature and should be considered to be an integral part of this document.

Note: APC documents can be accessed at www.cytometry.org.au

BACKGROUND

Failure to detect the presence in a recipient of preformed cytotoxic antibodies to donor Human Leukocyte Antigens (HLA) can have a devastating effect on a transplanted organ, particularly when it results in hyperacute rejection of the graft [(1,2)]. In haematopoietic stem cell and bone marrow transplants, these antibodies are associated with a high rate of graft rejection [(3)]. In Graft versus Host episodes, they can trigger anti-leukemia effects. These donor specific antibodies (DSA) typically develop in response to exposure to foreign HLA as a result of pregnancy, blood transfusion or transplant.

High concentrations of these antibodies are readily detectable with the complement dependent cytotoxicity (CDC) assay. However the flow cytometric crossmatch (FCXM) will also detect non-complement fixing antibodies [(4)], is 10 to 100 fold more sensitive [(5, 6)] and has been very effective in identifying clinically relevant lower levels of DSA that contribute to accelerated graft failure and early graft loss, not detectable by CDC [(7)].

HLA ALLOANTIBODY DETECTION - THE FLOW CYTOMETRIC LYMPHOCYTE CROSSMATCH.

The FCXM assay is performed by incubating lymphocytes from the potential donor with serum from the recipient. Any DSA in the patient serum will bind to the donor lymphocytes and be detected following a second incubation with a polyclonal anti-human immunoglobulin antibody (typically conjugated to fluorescein). Antibodies directed against class I HLA will bind to all lymphocytes while antibodies to class II HLA will only bind to B cells and other antigen presenting cells such as macrophages. A multicolour approach is used with the inclusion of two additional fluorochrome labelled monoclonal antibodies to allow identification of B and T cells (typically CD19 and CD3) to assist with antibody specificity. A significant increase in fluorescence of the cell in the patient serum relative to the negative control serum indicates the presence of DSA.

Pronase digestion of the lymphocytes prior to crossmatching, cleaves the Fc receptors, reducing nonspecific binding of antibody by the Fc receptor [(8, 9, 10)], particularly by B cells (which have relatively high numbers of Fc receptors on their cell surface). CD20 is also cleaved by pronase - digestion of B cells by pronase is a useful additional step in patients treated with Rituximab [(11)].

THE HALIFASTER PROTOCOL[(12)].

The standard FLXM assay including cell isolation can take 4-5 hours to complete. To reduce transplantation delays and ischaemia time, optimization of cell isolation, cell to serum ratio, incubation times and temperature have seen the *Halifaster protocol* being implemented in Canada and many North American laboratories. It is now in routine use in most laboratories in Australia and New Zealand.

Assays are performed on lymphocytes recovered from anti-coagulated blood, and serum.

1. PRE ANALYTICAL PHASE

Refer to ACS 'Guidelines for Clinical Flow Cytometry Laboratory Practice' for information regarding minimum specimen labelling requirements, request forms, collection and transport conditions in addition to those shown following.

G1.1 Specimen Collection

Universal precautions should be strictly observed when collecting and handling samples.

G1.1.1 All samples and their accompanying request forms must contain at least three unique identifiers for the individuals being tested.

C1.1.1 Typically this will be the individual's name and date of birth, but could be another unique code or identifier

G1.1.2 All specimen tubes must be individually labelled and include the date each sample was collected.

C1.1.2 Time should also be included, particularly when blood is collected from patients receiving IVIG.

G1.1.3 All test requests must identify the authorizing practitioner, along with the tests they are requesting.

G1.1.4 PBMCs can be recovered from peripheral blood (anti-coagulant present e.g. acid citrate dextrose (ACD), sodium heparin), Lymph node, Spleen, or thawed cryopreserved mononuclear cells.

G1.1.5 Cell specimens to be tested > 48 hours after collection should be treated with caution.

C1.1.5(i) Use of older blood must be noted on the worksheet and the report. The report should include a comment reflecting the effect this may have on the results.

C1.1.5(ii) PBMC viability should be > 80%. Nonviable cells may non-specifically bind to many antibodies and interfere with accurate detection of the presence of DSA. Where low viability is suspected, the use of a viability stain may be required e.g. 7AAD, Trypan Blue.

C1.1.5(iii) Where non-viable cells are suspected to have interfered, a disclaimer statement about suboptimal viability should be included in the report. Where significant DSA are detected, a repeat specimen may not be required.

G1.1.6 Serum samples: Blood must be clotted prior to serum being recovered for testing.

C1.1.6(i) Whole blood should be kept at room temperature for 1 hour to allow it to clot.

C1.1.6(ii) Serum can be stored at 4°C for up to 72 hours until testing [13].

C1.1.6(iii) Long term serum storage should occur at or below a temperature of -70°C (some IgG is always lost during freezing/thawing).

G1.1.7 There are no minimum volume requirements. Suggested are given below for Flow Cytometric Cross Match (FCXM) samples.

C1.1.7(i) Fresh blood specimens:

20 mLs anti-coagulated blood (ACD, heparin or equivalent) from the potential donor

10 mLs clotted blood from the potential recipient

20 mLs anti-coagulated blood (ACD, heparin or equivalent) from the potential recipient, if required. (An auto patient crossmatch is not mandatory - if blood is not obtainable, omission will not invalidate the test.)

C1.1.7(ii) Cryopreserved specimens:

5 x 106 cryopreserved PBMC

0.5 mLs serum

G1.2 Specimen Transport

G1.2.1 Packaging, labelling and transport of specimens should comply with the requirements for shipping of Biological Samples as Dangerous Goods [14, 15] along with any relevant local state based legislation.

G1.2.2 Fresh blood specimens should be maintained at 16-25oC using a leak-proof triple packaging system.

C1.2.2 Temperatures below 4°C, and above 30°C must be avoided.

G1.2.3 Serum shipped frozen on dry ice must be protected from CO_2 and conform with the Dangerous Goods requirements for Infectious substances and Dry Ice.

G1.3 Reagents

G1.3.1 Reagents must be stored according to manufacturer's instructions or in a manner documented to allow them to perform accurately and reliably when used in the assay.

G1.3.2 Manufacturer's instructions must be followed unless the laboratory has validated their modified use.

G1.3.3 Critical reagents should be placed in quarantine on arrival until pre-release testing can be completed to demonstrate they are satisfactory for use.

G1.3.4 All reagents and critical material must not be used past their expiry date unless they have been validated against in date reagents to demonstrate their performance remains equivalent and has not deteriorated.

C1.3.4 Reagents received without an expiration date must be given an appropriate expiry date using evidence demonstrating optimum performance is maintained for the duration of its shelf life.

G1.3.5 Each assay must document which reagent lot was used in that assay.

G1.4 Fluorochrome Labelled Antibodies

G1.4.1 FCXM antibody fluorochrome combinations should be selected to suit the local laboratory and their cytometer

G1.4.2 All new antibodies should be titrated to determine optimal sensitivity (Stain Index or signal to noise) or at a minimum, adequate separation of positive and negative peaks.

C1.4.2 Newly delivered antibodies may be tested at titrated levels in parallel with antibodies in use to verify their performance.

G1.4.3 A F(ab')2 anti-human IgG antibody specific for the Fc region should be used to assess binding of human IgG

G1.4.4 Antibodies should not cross react with any other multicolour reagent or foetal calf serum.

G1.4.5 Cocktail antibodies should (individually) undergo testing prior to use to demonstrate the performance of each new antibody Lot and /or delivery is equivalent to the current antibody.

G1.4.6 **Expired reagents can be used where their performance remains equivalent to that demonstrated in pre-release testing. Data must be available to support this.**

G1.5 Computer Software

G1.5.1 **All computer software programs (and version upgrades) used to transfer or analyse data, perform calculations and generate results and reports must undergo documented validation prior to use.**

C.1.5.1 A process must be in place to ensure the accuracy of computer analyses is maintained.

G1.5.2 **Where existing software is revised or corrected, a documented review of historic results must be performed to determine whether corrective action is required for any previously issued results or reports.**

2. ANALYTICAL PHASE

Refer to ACS *'Guidelines for Clinical Flow Cytometry Laboratory Practice'* for information regarding sample analysis and performance measures in addition to those shown following.

G2.1 Negative Control

G2.1.1 **The Negative FCXM control may be pooled human serum or serum from a single donor. It must be negative by both solid phase antibody screen and FCXM screen.**

C2.1.1(i) The FCXM screen should demonstrate low background staining for a panel of cells representative of your local potential donor population.

C2.1.1(ii) A good negative control will show a fluorescence shift only slightly above that observed for the same cells suspended in PBS alone.

C2.1.1(ii) Aliquots for use should be stored at -70°C until required.

C2.1.1(iii) Every time a new lot of negative control is selected, background staining and fluorescence should be comparable to the existing negative control, otherwise a new cut-off value needs to be determined. This should be done using a statistically significant sampling of flow crossmatch results on normal cells.

G2.2 Positive Control

G2.2 The positive control should consist of pooled positive sera from sensitised patients with broad HLA specificity and high anti-HLA IgG titre.

C2.2(i) The pool must include IgG specific for a broad range of HLA specificities in the local population.

C2.2(ii) Inclusion of anti-Bw4 and Bw6 would guarantee reactivity with most donor T and B cells.

C2.2(iii) Adding sera with anti-DRw51, anti-DRw52 and DRw53 reactivity may help for B cells, however this is not essential as Class 1 HLA antibodies bind to B cells.

C2.2(iv) Aliquots for use should be stored at -70°C until required.

C2.2(v) The pooled positive control may be assayed neat and at a dilution. The dilution is usually set slightly above the upper threshold of the negative control, i.e. a "borderline" or weakly positive reaction. This is to ensure consistency in determining the lower limits of a positive test.

G2.3 PBMC Isolation

G2.3.1 **Fresh PBMCs should be isolated from the sample according to the laboratory's standard protocols: Ficoll hypaque, a commercial equivalent e.g. Lymphoprep™, or a validated bead based method.**

C2.3.1 Avoid using Lympho-Kwik and Percoll containing reagents. These products increase background binding thereby reducing the sensitivity of the assay and may result in reporting a false negative result.

G2.3.2 **Removal of platelets is essential. Platelets are rich in HLA class 1 and if present in detectable numbers may cause a false negative result by competing with lymphocytes for antibody binding sites.**

G2.3.3 **Overall purity of the cell preparation should be > 90% lymphocytes. The total numbers of contaminating cells such as platelets, RBCs, and granulocytes should be < 10%.**

G2.4 Pronase Treatment

The proteolytic enzyme pronase can be used to treat PBMC prior to crossmatching. Pronase will cleave Fc receptors on the surface of B cells, and to a lesser extent, on T cells [9]. This decreases non-specific background fluorescence, enhancing the signal to noise ratio and improving specificity and sensitivity for B cells.

G2.4.1 **Ensure pronase treated cells are counted after digestion (some cells are lost during digestion).**

G2.4.2 **Pronase treated cells should be crossmatched within 2-3 hours after digestion before Fc receptors are re-generated and re-appear on the cell surface.**

C2.4.2(i) It is recommended that a control sample be included to monitor the performance of pronase. (e.g. measuring expression of CD20, which is cleaved by pronase)

C2.4.2(ii) Care must be taken with interpretation of pronase treated T cell results as pronase can result in a false positive result (16). (Other testing and results e.g. B cell FLXM, Luminex, CDC etc. should be considered to help interpretation.)

G2.4.3 The laboratory must establish an appropriate concentration of pronase that does not reduce HLA expression (17).

G2.5 Serum Samples

G2.5.1 Inclusion of a serum sample collected immediately prior to the crossmatch is preferred.

C2.5.1(i) An older serum may be used when a patient has been undergoing screening for some time and has had no known sensitising events since serum collection. However, this must be noted on the report.

C2.5.1(ii) As an option, the peak and/or other historic sera of interest from the patient may be used. Serum samples can be of any age but the date of collection must be included when reporting. These are likely to be frozen.

C2.5.1(iii) current serum from potential donor(s) may be used as an autologous control

G2.5.2 Frozen sera thawed for use should be centrifuged (10000g, 10 mins) prior to use to remove aggregated immunoglobulin, immune complexes and other precipitates.

C2.5.2(i) Aggregates can increase non-specific background staining, reducing sensitivity and increasing the risk of reporting falsely negative results

C2.5.2(ii) It should be noted aggregates can also include specific HLA antibody which has the effect of reducing the amount available for the assay.

C2.5.2(iii) Freshly isolated sera should be snap frozen and thawed prior to centrifugation.

G 2.6 Flow Cytometric Cross Match Assay

G2.6.1 An optimum serum to target ratio must be established. The cell number to serum ratio should remain constant e.g. 100,000 cells for every 10µl serum.

C2.6.1 Serum can be run undiluted or at a dilution established during validation. Where sera are diluted further, clear indication of the dilution must be included in the report.

G2.6.2 Assays must include antibodies to identify T cell and B cell populations, and detect clinically relevant IgG capable of binding to donor specific HLA class I and class II (and patient HLA where required).

G2.6.3 Cells may require fixation post staining with the Ab cocktail unless they are run on the cytometer within a few hours of completion of the antibody staining step.

C2.6.3(i) Fixed samples should be kept at 4°C in the dark and should be acquired within 24 hours.

C2.6.3(ii) Each laboratory should have a validated process for managing fixed samples.

G2.6.4 Adequate washing is required post crossmatch incubation to ensure all unbound IgG is removed prior to addition of the antibody cocktail.

G 2.7 Instrument Setup and Calibration [18].

G2.7.1 Calibration beads/fluorescent standards must be run each time the instrument is turned on, or following maintenance, adjustments or problems where instrument performance may be affected.

C2.7. 1 Assays using settings not linked to set up beads should have PMT/detector voltages set to allow dim signals to be resolved without significant contribution from underlying electronic noise.

G2.7.2 A fluorescent standard for each fluorochrome used in the assay should be included.

G2.7.3 Where more than one fluorochrome is in use, appropriate compensation of spectral overlap must be applied [(19)].

C2.7.3 This may be performed as part of the setup e.g. where 7-color beads are used for instrument setup and samples are acquired using settings linked link to lyse-wash settings or similar.

G2.7.4 Results for each run should be recorded along with an indication that all relevant parameters were accepted as satisfactory for that run.

G 2.8 Sample Acquisition

G2.8.1 Gating strategies need to ensure that the population of interest is being selected without significant contamination.

C2.8.1(i) B cells – acquire CD19 or CD20 positive cellular events. CD19must be used to identify pronase treated B cells (pronase cleaves CD20).

C2.8.1(ii) T cells – acquire CD3 positive cellular events.

G2.8.2 A minimum stop condition must be defined for routine assays e.g. 200 B cellular events.

G2.9 Performance Measures

G2.9.1 Replicate tubes/wells should agree within a defined range (e.g. ± 5.0%CV).

G2.9.2 Negative and Positive control sera should be tested and fall within defined ranges.

C2.9.2(i) The positive control value for a given assay can exceed the upper limit.

C2.9.2(ii) If the positive control value is below the lower limit, the assay must be repeated if the result appears negative.

G2.9.3 The threshold defining a positive result must be clearly defined during assay validation.

C.2.9.3 Where the positive result is graded (weak positive, strong positive), a table outlining the limits for each grade should be clearly included in the report.

G2.9.4 Each laboratory must participate in an external proficiency testing program.

C2.9.4(i) External QAP providers include, but are not restricted to

APHIA FLXM QAP

ASHI AC QAP (Serum Antibody Screening/Identification and Crossmatching)

UCLA FCXM QAP (Flow and Virtual Crossmatch Exchange)

NIBSC Flow Crossmatch QAP

C2.9.4(ii) The proficiency testing program should have a minimum of 2 send outs per year.

C2.9.4(iii) The proficiency testing program should include samples that assess the capacity to detect HLA Class I and Class II antibodies.

C2.9.4(iv) Laboratories must:

incorporate proficiency testing samples into the regular workload.

not refer any proficiency testing to an external laboratory.

3. POST ANALYTICAL PHASE

Refer to ACS *'Guidelines for Clinical Flow Cytometry Laboratory Practice'* for information regarding reports, record keeping, result validation, follow up tests in addition to those shown following.

3.1 Results

G3.1.1 Results should be reported for each B and T cell population.

G3.1.2 Each result should include clearly identified raw linear data, calculated channel shift or ratio, and the positive/negative result.

3.2 Reports

G3.2.1 The report must contain the sample name (including a second unique identifier), collection date(s) of each sample(s), specimen source/type and the date tested.

G3.2.2 The report must include a comment with appropriate advice on the crossmatch results in the context of the patient's antibody profile.

C3.2.2 Labs reporting untreated and pronase treated results should clearly indicate which treatment applies to which results on the report.

G3.2.3 An interpretive comment must be made involving a competent tissue typing flow cytometrist.

C3.2.3 Result interpretation should take into account HLA antibody results acquired by solid phase assay (Luminex technology) where available.

REFERENCES CITED

1. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldberg O. 'Hyperacute rejection of kidney allografts: association with pre-existing humoral antibodies against donor cells.' Lancet 1966; 2: 653.
2. Patel R, Terasaki PI. 'Significance of the positive crossmatch test in kidney transplantation.' N Engl J Med 1969; 280: 735.
3. Ciurea SO, de Lima M, Cano P, et al. 'High Risk of Graft Failure in Patients with Anti-HLA Antibodies Undergoing Haploidentical Stem Cell Transplantation.' Transplantation 2009; 88(8) 1019-24
4. Garovoy MR, Rheinschmidt MA, Bigos M, Perkins HA, Colombe B. 'Flow cytometry analysis: A high technology crossmatch technique facilitating transplantation.' Transplant Proc. 1983;15:1939–44.
5. Chapman JR, Deierhoi MH, Carter NP, Ting A, Morris PJ. 'Analysis of Flow Cytometry and Cytotoxicity Crossmatches in Renal Transplantation.' Transplant Proc. 1985: 17(6), 2480-2481
6. Bray RA, Lebeck LK, Gebel HM. 'The flow cytometric crossmatch: dual colour analysis of T and B cell reactivities.' Transplantation 1989; 48:834
7. Couzi L, Araujo C, Guidicelli G, et al. 'Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay.' Transplantation 2011; 91: 527.
8. Winkel JGJ, Van de Anderson CL. 'Biology of human immunoglobulin G Fc receptors.' J Leukoc Biol 1991; 49: 511.
9. Lobo PI, Spencer CE, Stevenson WC, et al: 'The use of pronase-digested human leukocytes to improve specificity of the flow cytometric crossmatch.' Transpl Int 8:472, 1995
10. Vaidya S, Cooper TY, Avandsalehi J, et al:' Improved flow cytometric detection of HLA alloantibodies using pronase: potential implications in renal transplantation.' Transplantation 71:422, 2001.

11. Bearden CM, Agarwal A, Book BK, Sidner RA, Gebel HM, Bray RA, Pescovitz MD. ‘Pronase Treatment Facilitates Alloantibody Flow Cytometric and Cytotoxic Crossmatching in the Presence of Rituximab. Human Immunology’ 2004; 65, 803-809
12. Liwski R, Greenshields A, Conrad D, Murphey C, Bray R A, Neumann J, Gebel H M. ‘Rapid optimized flow cytometric crossmatch (FCXM) assays: The Halifax and Halifaster protocols.’ Human Immunology 2018; 79, 28-38
13. ASHI 2014 Revised Standards approved by the ASHI Board of Directors Approved by CMS: 1/8/2015 Guidance Final Version October 2014; Revised October 2014
14. Requirements for the Packaging and Transport of Pathology Specimens and Associated Materials Fourth Edition 2013 NPAAC (NATIONAL PATHOLOGY ACCREDITATION ADVISORY COUNCIL).
15. Australian Code for the Transport of Dangerous Goods by Road and Rail Edition 7.5, 2017 NTC Australia (National Transport Commission).
16. Park H, Lim YM, Han BY, Hyun J, Song EY, Park MH. ‘Frequent False-Positive Reactions in Pronase-Treated T-Cell Flow Cytometric Cross-match Tests.’ Transplant Proc 2012; 44, 87-90.
17. Hetrick SJ, Schillinger KP, Zachary AA, Jackson AM. ‘Impact of pronase on flow cytometric crossmatch outcome.’ Human Immunol 2011; 72, 330-336
18. Maecker HT, Trotter J. ‘Flow Cytometry Controls, Instrument Setup, and the Determination of Positivity.’ Cytometry Part A 2006; 69A, 1037-1042.
19. Bagwell CB, Adams EG. ‘Fluorescence spectral overlap compensation for any number of flow cytometric parameters.’ Annals of the New York Academy of Sciences, New York, 1993: 677:94:167–184.

PROCEDURAL REFERENCES

For background on the methods, descriptions of methodology, interpretation and publications recommend:

1. Bray RA, Gebel HM, Ellis TM. ‘Flow Cytometric Assessment of HLA Alloantibodies.’ Current Protocols in Cytometry, 2004, Unit 6.16. Wiley and Sons.
2. Hahn A, Land G, Strothman R, et al. ‘ASHI Laboratory Manual’, 4th Edition Volume 1. 2000.

3. Skibby S, ‘Pronase.’ ASHI Lab Manual 2013
4. Standards for Accredited Laboratories, 2019 Revised Standards as approved by the ASHI Board of Directors. Approved by CMS: February 6 2020. Guidance Final Version November 2019; Revised November 2019.
5. Tait B, Süsal C, Gebel H, et al. ‘Consensus Guidelines on the Testing and Clinical Management Issues Associated with HLA and Non-HLA Antibodies in Transplantation.’ Transplantation 2013; 95 (1), 19 – 47

Editorial committee

Ian Nicholson, Senior Scientist TRA, Transplantation and Immunogenetics Services, Australian Red Cross Lifeblood, Melbourne, Australia.

Jonathan Downing, Medical Scientist in Charge, Transplant Immunology, Department of Clinical Immunology, Royal Perth Hospital, Perth, Australia.

Nathan Peacock, Medical Laboratory Scientist - National Tissue Typing Department New Zealand Blood Service, Auckland. New Zealand.

Dr Lyanne Weston, Acting Manager, Transplantation & Immunogenetics Service, Australian Red Cross Lifeblood, Sydney, Australia

Dr Jeremy McComish, Immunopathologist, Clinical Service and Research, Australian Red Cross Lifeblood, Melbourne Australia.

Dr Brian Tait, Scientific Consultant Haplomic Technologies, Associate Department of Medicine University of Melbourne, Melbourne Australia.

A/Prof Robert Carroll, Clinical Consultant (ASHI Lab Director Certified) Transplantation and Immunogenetics Service, Adelaide, Australia

Revision	Change Summary	Active Date	Author of Change
First Edition	• First Edition	2017	Ian Nicholson
Second Edition	• Added Section 2,1 Negative Control; Section 2.2 Positive Control • Definitions: removed DR51, DRB5 reference; • Background: addition of Halifaster Protocol Reference • C1.1.1 : remove reference to medical practitioner • C1.1.2 :removal reference to time of collection labelling • G1.1.3 : requests require authorizing practitioner identified • C1.1.5 : section added regarding sample viability staining • G1.3.3 : Storage or reagents pre testing • G1.4.4 : inclusion of stain index • C1.5.1 : computer accuracy reference • G2.1.1 (ii) comment added regarding negative controls • C2.5.2, C2.5.3 comments added • C2.6.1 added regarding serum dilution • C2.4.3.2 added regarding validation process • G2.7.1 section added regarding instrument setup and calibration • G2.9.3 : G2.7.3 edited regarding threshold definition and reporting • G2.9.4 Comments added expanding details of proficiency programs • C3.2.1 comment added regarding pronase treated result reporting • Reference and Procedural reference, Editorial lists updated	2020	Ian Nicholson

ACS guideline documents are available on the website: www.cytometry.org.au